| Pharmaceutical Information |
| Drug Name |
Levalbuterol tartrate |
| Drug ID |
BADD_D01264 |
| Description |
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
[Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). |
| Indications and Usage |
Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB13139
|
| KEGG ID |
D04703
|
| MeSH ID |
D064412
|
| PubChem ID |
10349032
|
| TTD Drug ID |
D02ZJI
|
| NDC Product Code |
50384-4188; 63402-510; 69988-0045; 63187-876; 0591-2927; 63629-8822 |
| UNII |
ADS4I3E22M
|
| Synonyms |
Levalbuterol | Xopenex | Levalbuterol Hydrochloride | Hydrochloride, Levalbuterol | Levosalbutamol Hydrochloride | Hydrochloride, Levosalbutamol |
|
| Chemical Information |
| Molecular Formula |
C30H48N2O12 |
| CAS Registry Number |
34391-04-3 |
| SMILES |
CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.C(C(C(=O)O)O)(
C(=O)O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
